{
    "type": "VariantTherapeuticResponseProposition",
    "predicate": "sensitivity",
    "description": "Treatment of pediatric patients with refractory classical Hodgkin lymphoma (cHL), or cHL that has relapsed after 2 or more lines of therapy",
    "geneContextQualifier": "--",
    "objectTherapeutic": "Pembrolizumab [Keytruda]"
}